Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ITRACONAZOLE

Form:

5 of 5 products shown

2 general benefit · 2 Limited Use · 1 not a benefit

Other products in the same Health Canada class (J02A, J02AC) — coverage varies; not interchangeable

  • Fluconazole (Diflucan P.O.S.): general benefit, Limited Use 528, Not a benefit
  • Voriconazole (Vfend): limited Use 399
  • Posaconazole (Posanol): not a benefit
  • Amphotericin b (Fungizone): general benefit
  • Ketoconazole (Nizoral): general benefit, Not a benefit
  • Caspofungin (Cancidas): not a benefit

1 more in the class list below

Jamp Itraconazole Oral Solution · DIN 02484315 · 10mg/mL · Oral Sol

Limited Use — Reason for Use code 570 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 570 required
Write on scriptLU code 570 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 570
Reason for Use code 570 For patients who are unable to swallow or tolerate solid oral dosage forms. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Jamp Itraconazole Oral Solution · DIN 02484315 Manufacturer: Jamp Pharma Corporation; listing date 2020-04-30 Health Canada: Marketed since 2019-07-31 · brand JAMP ITRACONAZOLE ORAL SOLUTION · ATC J02AC02 ITRACONAZOLE · form Solution · route Oral · ingredients ITRACONAZOLE 10 MG/ML · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Itraconazole Oral Solution: Formulary list price $0.4111/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4111 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97463 · Verify on the e-Formulary ↗ (DIN 02484315)

Source record
DIN 02484315: Jamp Itraconazole Oral Solution Raw flags: sec12=Y, sec3=Y Item: 081204043; group id 11; item number 0014; lccId 00327; manufacturer id JPC Source form: Oral Sol; strength: 10mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.4111; ministry $0.4111 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02484315 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97463
Interchangeable products
Odan-Itraconazole · DIN 02495988 · $0.4111 Sporanox · DIN 02231347 · not recorded
Shortage status: resolved shortage (ended 2026-04-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02484315
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Odan-Itraconazole · DIN 02495988 · 10mg/mL · Oral Sol

Limited Use — Reason for Use code 570 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 570 required
Write on scriptLU code 570 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 570
Reason for Use code 570 For patients who are unable to swallow or tolerate solid oral dosage forms. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Odan-Itraconazole · DIN 02495988 Manufacturer: Odan Laboratories Ltd.; listing date 2020-08-28 Health Canada: Marketed since 2020-07-08 · brand ODAN ITRACONAZOLE · ATC J02AC02 ITRACONAZOLE · form Solution · route Oral · ingredients ITRACONAZOLE 10 MG/ML · company Odan laboratoriesltd · schedule Prescription
Check this DIN again · Health Canada product record

Odan-Itraconazole: Formulary list price $0.4111/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4111 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98587 · Verify on the e-Formulary ↗ (DIN 02495988)

Source record
DIN 02495988: Odan-Itraconazole Raw flags: sec12=Y, sec3=Y Item: 081204043; group id 11; item number 0014; lccId 00327; manufacturer id ODN Source form: Oral Sol; strength: 10mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.4111; ministry $0.4111 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02495988 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98587
Interchangeable products
Jamp Itraconazole Oral Solution · DIN 02484315 · $0.4111 Sporanox · DIN 02231347 · not recorded
Shortage status: resolved shortage (ended 2021-12-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02495988
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Itraconazole · DIN 02462559 · 100mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mint-Itraconazole · DIN 02462559 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2017-07-31 Health Canada: Marketed since 2017-05-18 · brand MINT-ITRACONAZOLE · ATC J02AC02 ITRACONAZOLE · form Capsule · route Oral · ingredients ITRACONAZOLE 100 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Itraconazole: Formulary list price $3.9270/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.9270 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95031 · Verify on the e-Formulary ↗ (DIN 02462559)

Source record
DIN 02462559: Mint-Itraconazole Raw flags: sec3=Y Item: 081204040; group id 10; item number 0013; lccId None; manufacturer id MIN Source form: Cap; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $3.9270; ministry $3.9270 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02462559 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95031
Interchangeable products
Sporanox · DIN 02047454 · $3.9270
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02462559
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sporanox · DIN 02047454 · 100mg · capsule

General benefit; Health Canada lists this DIN as Cancelled post market since 2026-04-01 — choose a marketed DIN from the same-category list.Discontinued 2026-04-01 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-04-01 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-04-01 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Sporanox (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Sporanox · DIN 02047454 Manufacturer: Janssen Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2026-04-01 · brand SPORANOX · ATC J02AC02 ITRACONAZOLE · form Capsule · route Oral · ingredients ITRACONAZOLE 100 MG · company Janssen inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $3.9270 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14518 · Verify on the e-Formulary ↗ (DIN 02047454)

Source record
DIN 02047454: Sporanox Raw flags: sec3=Y Item: 081204040; group id 10; item number 0013; lccId None; manufacturer id JAN Source form: Cap; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $6.6750; ministry $3.9270 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02047454 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14518
Interchangeable products
Mint-Itraconazole · DIN 02462559 · $3.9270
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02047454
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2026-04-01 — choose a marketed DIN from the same-category list.

Sporanox · DIN 02231347 · 10mg/mL · Oral Sol

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-09-29 — choose a marketed DIN from the same-category list.Discontinued 2023-09-29 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-09-29 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2023-09-29 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 570
Reason for Use code 570 For patients who are unable to swallow or tolerate solid oral dosage forms. Coverage limit: LU Authorization Period: 1 year
Savings card: RxHelp ONE lists Sporanox (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Sporanox · DIN 02231347 Manufacturer: Janssen Inc.; listing date 1998-12-31 Health Canada: Cancelled post market since 2023-09-29 · brand SPORANOX · ATC J02AC02 ITRACONAZOLE · form Solution · route Oral · ingredients ITRACONAZOLE 10 MG/ML · company Janssen inc · schedule Prescription
Check this DIN again · Health Canada product record

Sporanox: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50656 · Verify on the e-Formulary ↗ (DIN 02231347)

Source record
DIN 02231347: Sporanox Raw flags: notABenefit=Y, sec3=Y Item: 081204043; group id 11; item number 0014; lccId 00327; manufacturer id JAN Source form: Oral Sol; strength: 10mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02231347 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50656
Interchangeable products
Jamp Itraconazole Oral Solution · DIN 02484315 · $0.4111 Odan-Itraconazole · DIN 02495988 · $0.4111
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02231347
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2023-09-29 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:12:04 Antifungals) and how they are covered

Matched class: 08:12:04 Antifungals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMPHOTERICIN B Some products covered without a code (check the product listing): FLUCONAZOLE, KETOCONAZOLE, NYSTATIN, TERBINAFINE HCL 08:12:04 Antifungals

FLUCONAZOLE

· 17 products · Limited Use, codes 528 (1), Listed, not a benefit (2), General benefit (14) · strengths: 10mg/mL, 50mg, 100mg · O/L, Tab

VORICONAZOLE

· 6 products · Limited Use, codes 399 · strengths: 50mg, 200mg · Tab

POSACONAZOLE

· 7 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 40mg/mL · DR Tab, O/L

AMPHOTERICIN B

· 1 products · General benefit · strengths: · Inj Pd-50mg Pk

KETOCONAZOLE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 200mg · Tab

CASPOFUNGIN ACETATE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg/Vial · Inj-Vial Pk

MICAFUNGIN SODIUM

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg/Vial, 100mg/Vial · Inj Pd-10mL Vial Pk

NYSTATIN

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 100000U/mL · O/L

TERBINAFINE HCL

· 8 products · Listed, not a benefit (1), General benefit (7) · strengths: 250mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:04
Full class listing Related classes: 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS MINT-ITRACONAZOLE (itraconazole) capsules are indicated for: • the treatment of the following systemic fungal infections in normal, predisposed or immunocompromised patients: 1. Invasive and non-invasive pulmonary aspergillosis. 2. Oral and/or esophageal candidiasis. 3. Chronic pulmonary histoplasmosis. 4. Cutaneous and lymphatic sporotrichosis. 5. Paracoccidioidomycosis. 6. Chromoblastomycosis.(formerly chromomycosis) 7. Blastomycosis. The type of organism responsible for the infection should be isolated and identified and other relevant laboratory studies (wet mount, histopathology, serology) should be undertaken as appropriate to confirm diagnosis. Therapy may be initiated prior to obtaining these results when clinically warranted; however, once these results become available, antifungal therapy should be adjusted accordingly. • the treatment of the following topical fungal infections in normal, predisposed or immunocompromised patients: 8. Dermatomycoses due to tinea corporis, tinea cruris, tinea pedis, and pityriasis versicolor, where … https://pdf.hres.ca/dpd_pm/00082400.PDF PM date: OCT 27, 2025 Source product: MINT-ITRACONAZOLE; DIN 02462559; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Sporanox · DIN 02047454 Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02047454

Check this DIN again

Sporanox · DIN 02231347 Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02231347

Check this DIN again

Other review policies

For Sporanox: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026